Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Share :
Published: 5 Jun 2022
Views: 116
Dr Martin McCabe- University of Manchester, Manchester, England

Dr Martin McCabe presents his study on chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). rEECur is the first randomised controlled trial in this setting.

The primary outcome was event-free survival (EFS) for the phase III comparison. Secondary outcomes included overall survival (OS), toxicity, and quality of life (QoL).

He concludes the presentation by discussing his findings of the study.

Watch Dr McCabe's interview on the study here

Watch Dr Gralow comment on the study here

Read the news story here